157 results on '"Wind-Rotolo, Megan"'
Search Results
2. Disease-free Survival Analysis for Patients with High-risk Muscle-invasive Urothelial Carcinoma from the Randomized CheckMate 274 Trial by PD-L1 Combined Positive Score and Tumor Cell Score
3. Landscape of helper and regulatory antitumour CD4+ T cells in melanoma
4. HLA-A*03 and response to immune checkpoint blockade in cancer: an epidemiological biomarker study
5. Integrative Tumor and Immune Cell Multi-omic Analyses Predict Response to Immune Checkpoint Blockade in Melanoma
6. Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma
7. Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma
8. Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma
9. Glycolytic activity and in vitro effect of the pyruvate kinase activator AG‐946 in red blood cells from low‐risk myelodysplastic syndromes patients: A proof‐of‐concept study.
10. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma
11. The Fast Real-time Assessment of Combination Therapies in Immuno-ONcology (FRACTION) program: innovative, high-throughput clinical screening of immunotherapies
12. Effects of a Fixed-Dose Co-Formulation of Daclatasvir, Asunaprevir, and Beclabuvir on the Pharmacokinetics of a Cocktail of Cytochrome P450 and Drug Transporter Substrates in Healthy Subjects
13. Peginterferon lambda for the treatment of HBeAg-positive chronic hepatitis B: A randomized phase 2b study (LIRA-B)
14. Development of a prognostic composite cytokine signature based on the correlation with nivolumab clearance: translational PK/PD analysis in patients with renal cell carcinoma
15. Randomized trial of daclatasvir and asunaprevir with or without PegIFN/RBV for hepatitis C virus genotype 1 null responders
16. Efficacy of an Interferon- and Ribavirin-Free Regimen of Daclatasvir, Asunaprevir, and BMS-791325 in Treatment-Naive Patients With HCV Genotype 1 Infection
17. CANCER: Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma
18. 1504: IMMUNE CHECKPOINT INHIBITORS IN SEPSIS: A PHASE 1B TRIAL OF ANTI-PD-L1 (BMS-936559)
19. A Phase 2a/2b Multicenter Study of AG-946 in Patients with Anemia Due to Lower-Risk Myelodysplastic Syndromes
20. Pharmacodynamics, Safety, and Pharmacokinetics of BMS-663068, an Oral HIV-1 Attachment Inhibitor in HIV-1-Infected Subjects
21. Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial
22. Identification of Nevirapine-Resistant HIV-1 in the Latent Reservoir after Single-Dose Nevirapine to Prevent Mother-to-Child Transmission of HIV-1
23. Corrigendum to “Disease-free Survival Analysis for Patients with High-risk Muscle-invasive Urothelial Carcinoma from the Randomized CheckMate 274 Trial by PD-L1 Combined Positive Score and Tumor Cell Score” [Eur. Urol. 83(5) (2024) 432–440]
24. Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study
25. PB1990: GLYCOLYTIC ACTIVITY AND EFFECT OF EX‐VIVO TREATMENT WITH THE PYRUVATE KINASE (PK) ACTIVATOR AG‐946 IN RED BLOOD CELLS FROM LOW‐RISK MYELODYSPLASTIC SYNDROMES PATIENTS: A PROOF‐OF‐CONCEPT STUDY.
26. P717: AG946, A PYRUVATE KINASE (PK) ACTIVATOR IMPROVES PK PROPERTIES AND RED BLOOD CELL (RBC) METABOLISM UPON EX VIVO TREATMENT OF RBCS FROM PATIENTS WITH MYELODYSPLASTIC SYNDROMES.
27. The Pyruvate Kinase (PK) Activator AG-946 Improves PK Properties and Red Blood Cell (RBC) Characteristics upon Ex Vivo treatment of RBCs from Patients with Myelodysplastic Syndromes
28. Evaluation of Red Cell Deformability in Sickle Cell Disease Patients, Sickle Cell Carriers, and Healthy Controls Using Lorrca-Derived Parameters
29. AG-946, an Activator of Pyruvate Kinase, Improves Ineffective Erythropoiesis in the Bone Marrow of Mouse Models of Myelodysplastic Syndromes
30. Biochemical and Metabolomic Analysis of Glycolytic Activity in Red Blood Cells from Low-Risk Myelodysplastic Syndromes (LR-MDS) Patients and in-Vitro Effect of the Pyruvate Kinase Activator AG-946
31. Long-Term Safety and Efficacy of Mitapivat, an Oral Pyruvate Kinase Activator, in Adults with Sickle Cell Disease: Extension of a Phase 1 Dose Escalation Study
32. Analysis of innate and adaptive host immunity during combination therapy with peginterferon Lambda-1a and Entecavir in patients with HBeAg(+) chronic hepatitis B: 219
33. Daclatasvir plus Sofosbuvir for Previously Treated or Untreated Chronic HCV Infection
34. Landscape of helper and regulatory antitumour CD4+ T cells in melanoma.
35. Asunaprevir in Japanese Subjects in Phase 2: Exposure-Safety Versus US/EU-Based Subjects and Preliminary Assessment of Correlation with Single Nucleotide Polymorphisms (SNPs) in Liver Uptake Transporters: 1884
36. Pegylated Interferons Lambda-1a and Alfa-2a Display Different Gene Induction and Cytokine Release Profiles in Both Human Hepatocytes and Peripheral Blood Mononuclear Cells: 1885
37. Effect of Hepatic Impairment on the Pharmacokinetics of Asunaprevir (BMS-650032, ASV): 1873
38. Baseline CXCR3 Ligand Levels are Associated With Early Virologic Response to Treatment With Peginterferon Lambda-1a in Chronic Hepatitis C Patients in a Phase 2b Study: 1870
39. Characterization of HCV NS5A Resistance Variants in Naive Patients Infected with Genotypes 2 and 3 Receiving Short-Term Treatment of Daclatasvir in Combination with Pegylated Interferon-Alfa and Ribavirin: 795
40. Daclatasvir, an NS5A Replication Complex Inhibitor, Combined With Peginterferon Alfa-2a and Ribavirin in Treatment-Naive HCV-Genotype 1 or 4 Subjects: Phase 2b COMMAND-1 SVR12 Results: 755
41. Sustained Virologic Response in Chronic HCV Genotype (GT) 1-Infected Null Responders With Combination of Daclatasvir (DCV; NS5A Inhibitor) and Asunaprevir (ASV; NS3 Inhibitor) With or Without Peginterferon Alfa-2a/Ribavirin (PEG/RBV): 79
42. Preliminary Study of Two Antiviral Agents for Hepatitis C Genotype 1
43. Genomic analyses and immunotherapy in advanced melanoma
44. Brief Report: The HBV Drug Entecavir - Effects on HIV-1 Replication and Resistance
45. AG-946 Normalizes Glycolysis and Improves Red Cell Indices in a Humanized Sickle Cell Mouse Model
46. Mechanisms of HIV-1 escape from immune responses and antiretroviral drugs
47. Inhibition of human immunodeficiency virus type 1 replication by siRNA targeted to the highly conserved primer binding site
48. Inosine Triphosphate Pyrophosphatase Dephosphorylates Ribavirin Triphosphate and Reduced Enzymatic Activity Potentiates Mutagenesis in Hepatitis C Virus
49. Analysis of Gene Induction and Arrest Site Transcription in Yeast with Mutations in the Transcription Elongation Machinery
50. Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.